Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for ImmunityBio (IBRX) over the last 8 years, with Q3 2025 value amounting to $177000.0.

  • ImmunityBio's Other Operating Expenses changed N/A to $177000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $371000.0, marking a year-over-year decrease of 5812.64%. This contributed to the annual value of $886000.0 for FY2023, which is 3010.28% up from last year.
  • As of Q3 2025, ImmunityBio's Other Operating Expenses stood at $177000.0.
  • In the past 5 years, ImmunityBio's Other Operating Expenses registered a high of $886000.0 during Q4 2023, and its lowest value of $58000.0 during Q1 2025.
  • Moreover, its 3-year median value for Other Operating Expenses was $177000.0 (2025), whereas its average is $387600.0.
  • The largest annual percentage gain for ImmunityBio's Other Operating Expenses in the last 5 years was 3010.28% (2023), contrasted with its biggest fall of 3010.28% (2023).
  • Quarter analysis of 3 years shows ImmunityBio's Other Operating Expenses stood at $681000.0 in 2022, then skyrocketed by 30.1% to $886000.0 in 2023, then tumbled by 80.02% to $177000.0 in 2025.
  • Its Other Operating Expenses was $177000.0 in Q3 2025, compared to $136000.0 in Q2 2025 and $58000.0 in Q1 2025.